Market Overview

GW Pharma Beats Q4 EPS Estimates, Misses On Revenue

GW Pharma Beats Q4 EPS Estimates, Misses On Revenue

GW Pharmaceuticals plc (NASDAQ: GWPH) reported financial results for its fiscal fourth quarter 2018. Compared to analysts' consensus estimates, the company reported a better-than-expected net loss, but its top line missed the expectations.

What Happened

For the quarter ended Sept. 30, GW Pharmaceuticals posted a net loss of 23 cents per share, which was narrower than the consensus estimate of a loss of $2.46. Revenue of $2.42 million was substantially lower than the expected $5.48 million and slightly below the $2.45 million the company posted for the fourth quarter of fiscal 2017.

For the full year, GW Pharma reported a net loss of 88 cents per share, compared to a loss of 56 cents per share a year earlier. Revenue came in at $12.74 million, up 47.6 percent on the year.

Why It's Important

GW Pharmaceuticals has the only FDA-approved CBD drug, Epidiolex, which was approved for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome. Epidiolex was launched for sale in the U.S. on Nov. 1.

The company also has another cannabis-based drug, Sativex, which is approved for cancer pain and multiple sclerosis spasticity in the UK and certain other markets.

What's Next

The company's pipeline includes a number of candidates at various trial stages. Sativex is undergoing late-stage trials in the U.S. for Multiple Sclerosis spasticity and the company is expecting a meeting with the FDA regarding the drug in December. Epidiolex is expected to launch in Europe next year.

In 2019, analysts expect GW Pharmaceuticals to generate a revenue of $139.23 million.

After falling about 4.7 percent in Tuesday's session, GW Pharma shares were marginally higher in after-hours trading. The stock closed at $121.72.

The Benzinga Cannabis Capital Conference is the premier gathering of cannabis entrepreneurs and investors in North America. Click here to learn more about the event, which takes place Jan. 15-16 in Miami, Florida.

Related links:

Additional Late-Stage Study Confirms Efficacy, Safety Of GW Pharma's Epidiolex

Curaleaf's Revenue Growth Nearly Quadrupled In Q3

Posted-In: Epidiolex sativexCannabis Earnings News After-Hours Center Markets Best of Benzinga


Related Articles (GWPH)

View Comments and Join the Discussion!

Cannabis Movers

Sign up for our secret cannabis newsletter!
Never miss out on the breaking news in the Cannabis Industry!

4 Stocks Moving In Tuesday's After-Hours Session

Morgan Stanley: Taubman Could Be More Attractive M&A Candidate Than Macerich